Skip to main content
. 2020 Jul 14;11(28):2747–2762. doi: 10.18632/oncotarget.27668

Table 2. TMEM165 expression in IDC vary by molecular subtypes.

Subtype Hormonal Status Percentage of Breast invasive carcinoma cases showing alterations in TMEM165 gene expressiona
Luminal A ER+ and/or PR+, HER2, low Ki67 2%
Luminal B ER+ and/or PR+, HER2 (or HER2- with high Ki67) 9%
Triple negative/Basal like ER-, PR-, HER2- 15%
Her 2 ER-, PR-, HER2+ 27%

aDatabase used was The Cancer Genome Atlas (TCGA), Nature (2012).